There were 1,636 press releases posted in the last 24 hours and 467,844 in the last 365 days.

National Survey of Health Plan Brokers Reveals Growth for Referenced-Based Pricing

Image of Scott Vold, Chief Commercial Officer at Renalogic

Scott Vold, Chief Commercial Officer

Renalogic Logo

Renalogic releases industry report featuring trends to combat massive claims

The respondents confirmed that demand for referenced-based pricing is growing as brokers learn more about the advantages of using cost containment to protect health plan assets.”
— Scott Vold, Renalogic, Chief Commercial Officer
PHOENIX, AZ, UNITED STATES, November 9, 2021 / -- Renalogic, the industry leader in dialysis risk management and cost containment, sponsored market research with the country’s top benefits consultants to gauge frontline perspective on the evolution of reference-based pricing (RBP) programs. With survey respondents expecting 4-7x growth in the utilization of RBP by their clients over the next three years, savvy brokers are adopting RBP for massive plan savings.

“Forty percent of brokers said none of their clients use RBP today and fewer than 30% said they were somewhat or very familiar with RBP solutions,” Scott Vold, Chief Commercial Officer at Renalogic said. “The respondents confirmed that demand for referenced-based pricing is growing as brokers learn more about the advantages of using cost containment to protect health plan assets.”

The research survey clearly indicates that dialysis may be a specific situation where RBP can be aggressively adopted. Because dialysis is a relatively low-incidence, high-cost situation, employee abrasion fears are largely mitigated, if not wholly eliminated. It is much easier for an employer and vendor to support, work with and explain RBP to just a few dialysis patients on a health plan, than 40-50% of members who might use a hospital-based service that is impacted by a general RBP plan.

The industry survey was conducted from September 15 through October 10, 2021. Here are some more key findings:

Traction is growing particularly for high-cost patient management with specific diseases.
The survey asked how likely brokers are to recommend a RBP program to manage costs for:
dialysis, diabetes, transplant, orthopedic, oncology, pharmacy, long-term acute care (hospital), surgery, cardiac, behavioral health, and acute/inpatient claims. Responses show a healthy interest in presenting the RBP option “some of the time” for all categories. Additionally, diabetes, dialysis, and transplant showed on average close to 20 percent of brokers willing to recommend RBP for those conditions “all the time.” Employers are laser-focused on disease prevention, management, and cost avoidance as a top priority.

Kidney disease is the most preferred disease category for RBP.
While brokers believe that a minority of their clients are using RBP for dialysis claims today, brokers rank dialysis as the leading category that they are willing to recommend for RBP. Interestingly, the related categories of transplant and diabetes were next highest. Medical claims data can identify members at all stages of diagnosed chronic kidney disease and kidney impairment, but typical large case management models do not have a program that focuses on the issue of kidney disease, end-to-end renal care, or renal cost-management solutions.

Benefits consultants are still learning about vendor partners.
When presented with a list of leading RBP vendors, 40-50 of brokers could provide a clear perception of any of the individual companies. While the survey sponsor, Renalogic, was the highest ranked in terms of perception, the overall lack of familiarity with vendors suggests that brokers would benefit from additional education around the performance and pros and cons of RBP vendors.

See the full report at

About Renalogic
Renalogic has been the industry leader in dialysis cost containment for nearly 20 years and continues to innovate through the impact of the Kidney Dialysis Avoidance Program. We are revolutionizing the industry by delivering predictive analytics to identify the progression of the disease, simplifying the costs and clinical complexities of chronic kidney disease to make a positive impact and reduce the dialysis incidence rate in every population we touch. Nearly every chronic condition leading to End Stage Renal Disease is manageable and even preventable when identified early. For more information, please visit
# # #

Carolyn S Tedore